Roche Holding AG Stock price

Equities

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe 07:42:05 2024-03-19 am EDT 5-day change 1st Jan Change
227.4 CHF -0.98% Intraday chart for Roche Holding AG -7.09% -6.99%
Sales 2024 * 59.43B 66.83B Sales 2025 * 63.06B 70.92B Capitalization 184B 207B
Net income 2024 * 12.99B 14.61B Net income 2025 * 14.47B 16.28B EV / Sales 2024 * 3.32 x
Net Debt 2024 * 13.23B 14.87B Net Debt 2025 * 7.16B 8.05B EV / Sales 2025 * 3.04 x
P/E ratio 2024 *
14.1 x
P/E ratio 2025 *
12.6 x
Employees 103,605
Yield 2024 *
4.18%
Yield 2025 *
4.34%
Free-Float 88.06%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

1 day-0.52%
1 week-5.12%
Current month-1.01%
1 month+0.61%
3 months-6.36%
6 months-10.99%
Current year-6.09%
More quotes
1 week
228.10
Extreme 228.1
244.75
1 month
227.30
Extreme 227.3
245.55
Current year
222.75
Extreme 222.75
255.90
1 year
222.75
Extreme 222.75
293.55
3 years
222.75
Extreme 222.75
404.20
5 years
222.75
Extreme 222.75
404.20
10 years
206.35
Extreme 206.35
404.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 65 95-12-31
More insiders
Date Price Change Volume
24-03-19 227.4 -0.96% 348 149
24-03-18 229.6 -0.52% 928,192
24-03-15 230.8 -0.69% 5,852,354
24-03-14 232.4 -3.57% 1,964,137
24-03-13 241 -1.53% 1,862,536

Delayed Quote Swiss Exchange, March 18, 2024 at 12:31 pm EDT

More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
229.6 CHF
Average target price
281.3 CHF
Spread / Average Target
+22.51%
Consensus
  1. Stock
  2. Equities
  3. Stock Roche Holding AG - Swiss Exchange